natgillin/translations-raw huggingface dataset:
The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA studies I, II and III.
Odstotek bolnikov, zdravljenih z zdravilom Humira, ki so dosegli odziv 20, 50 in 70 po ACR, se je v študijah revmatoidnega artritisa I, II in III skladal.
The percent of subjects with reported on-treatment events of major hypoglycemia (defined as an event that required assistance of another person) was higher in the saxagliptin group than in the placebo group (2.1% and 1.6%, respectively).
Odstotek preiskovancev, ki so med zdravljenjem poročali o hujši hipoglikemiji (ta je bila opredeljena kot dogodek, ki je zahteval pomoč druge osebe), je bil med prejemniki saksagliptina višji (2,1 %) kot med prejemniki placeba (1,6 %).
The percent reduction at 12 weeks for sildenafil 20 mg, 40 mg and 80 mg TID in PVR (11.2 %, 12.9 %, 23.3 %) was proportionally greater than the reduction in systemic vascular resistance (SVR) (7.2 %, 5.9 %, 14.4 %).
Odstotek znižanja pljučne žilne upornosti (11,2 % za 20 mg trikrat na dan, 12,9 % za 40 mg trikrat na dan in 23,3 % za 80 mg trikrat na dan) je bil po 12 tednih proporcionalno večji kot znižanje sistemske žilne upornosti (7,2 % za 20 mg trikrat na dan, 5,9 % za 40 mg trikrat na dan in 14,4 % za 80 mg trikrat na dan).
The percentage of ACR 20 responders was clinically relevant for the Cimzia 200 mg every 2 weeks and Cimzia 400 mg every 4 weeks treatment groups compared to placebo group at every visit after baseline through Week 24 (nominal p≤0.001 at each visit).
Delež odzivov ACR 20 je bil klinično pomembnem pri vsakem obisku od začetka zdravljenja do 24. tedna (nominalni p ≤0,001 pri vsakem obisku) pri skupini, ki je prejemala 200 mg zdravila Cimzia vsaka 2 tedna, in skupini, ki je prejemala 400 mg zdravila Cimzia vsake 4 tedne, v primerjavi s placebo.
The percentage of cefovecin resistant isolates in coagulase negative Staphylococci spp. (e.g.
Delež na cefovecin rezistentnih izolatov pri koagulaza negativnih Staphylococci spp. (npr.
The percentage of cefovecin resistant isolates in coagulase negative Staphylococcus spp. (e.g.
Delež na cefovecin rezistentnih izolatov pri koagulaza negativnih Staphylococcus spp. (npr.
The percentage of cefovecin resistant isolates in E. coli, Prevotella oralis, Bacteroides spp. and Proteus spp. were 2.3 %, 2.7 %, 3.1 % and 1.4 %, respectively.
Deleži na cefovecin rezistentnih izolatov pri E. coli, Prevotella oralis, Bacteroides spp. in Proteus spp. so bili 2,3 %, 2,7 %, 3,1 % in 1,4 %.
the percentage of deep partial thickness wounds requiring excision or dermabrasion, and the percentage of deep partial thickness wounds autografted.
odstotek globokih dermalnih ran, ki jih je bilo treba naknadno čistiti z ekscizijo ali dermabrazijo, in odstotek globokih dermalnih ran, oskrbljenih z avtotransplantati.
The percentage of IgG subclasses is approximately 66.6% IgG1, 27.9% IgG2, 3.0% IgG3 and 2.5% IgG4.
Odstotki podrazredov IgG znašajo približno 66,6 % IgG1, 27,9 % IgG2, 3,0 % IgG3 in 2,5 % IgG4.
The percentage of patients achieving HIV-1 RNA <50 copies/ml at Week 24 was lower in the paediatric patients receiving lopinavir/ritonavir tablets once daily (88.2%) than in patients receiving the twice-daily dosing (96.6%, p = 0.040), mainly due to lower adherence in the once-daily group.
Odstotek bolnikov, ki je dosegel HIV-1 RNA < 50 kopij/ml, je bil v 24. tednu pri pediatričnih bolnikih, ki so prejemali tablete z lopinavirjem/ritonavirjem enkrat na dan (88.2%) nižji kot pri bolnikih, ki so tablete prejemali dvakrat na dan (96.6%, p = 0.040), predvsem zaradi nižje adherence v skupini, ki je tablete prejemala enkrat na dan.
The percentage of patients achieving HIV-1 RNA <50 copies/ml at Week 24 was lower in the paediatric patients receiving lopinavir/ritonavir tablets once daily (88.2%) than in patients receiving the twice-daily dosing (96.6%, p = 0.040), mainly due to lower adherence in the once-daily group.
Odstotek bolnikov, ki so dosegli HIV-1 RNA <50 kopij/ml v 24. tednu je bil manjši pri pediatričnih bolnikih, ki so prejemali lopinavir/ritonavir tablete enkrat na dan (88,2 %) kot pri bolnikih, ki so prejemali odmerek dvakrat na dan (96,6 %, P=0,040), zlasti zaradi manjšega sodelovanja bolnikov v skupini, ki je prejemala odmerek enkrat na dan.
The percentage of patients achieving HIV-1 RNA <50 copies/ml at Week 24 was lower in the paediatric patients receiving lopinavir/ritonavir tablets once daily (88.2%) than in patients receiving the twice-daily dosing (96.6%, p = 0.040), mainly due to lower adherence in the once-daily group.
Odstotek bolnikov, ki so dosegli HIV-1 RNA <50 kopij/ml v 24. tednu je bil manjši pri pediatričnih bolnikih, ki so prejemali lopinavir/ritonavir tablete enkrat na dan (88,2 %), kot pri bolnikih, ki so prejemali odmerek dvakrat na dan (96,6 %, P=0,040), zlasti zaradi manjšega sodelovanja bolnikov v skupini, ki je prejemala odmerek enkrat na dan.
The percentage of patients aged 65 or over was not significantly different between the lenalidomide/dexamethasone and placebo/dexamethasone groups.
Odstotek bolnikov, starih 65 let ali več, se med skupinama, ki sta prejemali lenalidomid/deksametazon in placebo/deksametazon, ni bistveno razlikoval.
The percentage of patients receiving inhaled antibiotics was 55% in study DPM-CF-301 and 56% in study DPM-CF-302.
Prejemnikov inhaliranih antibiotikov je bilo v študiji DPM-CF-301 55 % preiskovancev, v študiji DPM-CF-302 pa 56 %.
The percentage of patients reporting ADRs upon re-treatment with further courses of MabThera was similar to the percentage of patients reporting ADRs upon initial exposure (any grade and grade 3/4 ADRs).
Odstotek bolnikov, pri katerih so se po ponovnem zdravljenju z zdravilom MabThera pojavili neželeni učinki, je bil podoben kakor po prvem zdravljenju (za neželene učinke katere koli stopnje in 3. ali 4. stopnje).
The percentage of patients who developed antibodies to albiglutide on treatment was 4% (128/2,934).
Med zdravljenjem so se protitelesa proti albiglutidu pojavila pri 4 % (128/2.934) bolnikov.
The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients).
Tudi odstotek bolnikov, ki so razvili nova pozitivna avtoprotitelesa proti dvojno vijačni DNA, je bil večji, merjeno z radioimunskimi testi (15 % pri zdravilu Enbrel in 4 % pri placebu) in s testom na Crithidia luciliae (3 % pri zdravilu Enbrel in 0 % pri placebu).
The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with etanercept compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with etanercept compared to none of placebo-treated patients).
Tudi odstotek bolnikov, ki so razvili nova pozitivna avtoprotitelesa proti dvojno vijačni DNA, je bil večji, merjeno z radioimunskimi testi (15 % pri etanerceptu in 4 % pri placebu) in s testom na Crithidia luciliae (3 % pri etanerceptu, in 0 % pri placebu).
The percentage of patients who experienced adverse reactions was lower in a smaller study (19.5%, 10.4%, 10.7% after the first, second and third infusion, respectively), where prophylaxis against adverse reactions was used.
V manjši študiji, v kateri so uporabljali profilakso proti neželenim učinkom, so bili deleži vseh bolnikov, pri katerih je prišlo do neželenih učinkov, nižji, in sicer po prvi infuziji 19,5 %, po drugi infuziji 10,4 %, po tretji infuziji pa 10,7%.
The percentage of patients who experienced adverse reactions was lower in a smaller study (19.5%, 10.4%, 10.7% after the first, second and third infusion, respectively), where prophylaxis against adverse reactions was used.
V manjši študiji, v kateri so uporabljali spodaj opisano profilakso proti neželenim učinkom, so bili deleži vseh bolnikov, pri katerih je prišlo do neželenih učinkov, nižji, in sicer po prvi infuziji 19,5 %, po drugi infuziji 10,4 %, po tretji infuziji pa 10,7 %.
The percentage of patients who had not smoked at all during weeks 9-12 was 44% with Champix, 30% with bupropion, and 18% with placebo.
12. tedna, je bil pri zdravilu Champix 44 %, pri bupropionu 30 % in pri placebu 18 %.
The percentage of patients who lost 5% and 10% of their baseline body weight after 1 year of treatment are given in table 2:
Spodaj v tabeli 2 so prikazani deleži bolnikov, ki so imeli po 1 letu zdravljenja telesno maso za 5 % oz.
The percentage of patients with Grades 3-4 neutropenia (neutrophil counts < 0.75 x 109/L) was higher in boceprevir-treated patients (29%) than in placebo-treated patients (17%), in combination with peginterferon alfa-2b and ribavirin.
Odstotek bolnikov z nevtropenijo 3. do 4. stopnje (število nevtrofilcev < 0,75 x 109/l) je bil večji med bolniki, ki so prejemali boceprevir (29 %), kot med bolniki, ki so prejemali placebo (17 %), v kombinaciji s peginterferonom alfa-2b in ribavirinom.
The percentage of patients with heart rate values <50 bpm on treatment was 11% for patients who received lumacaftor/ivacaftor, compared to 4.9% for patients who received placebo.
Odstotni delež bolnikov z vrednostmi srčne frekvence <50 bpm med zdravljenjem je bil 11 % pri bolnikih, zdravljenih z lumakaftorjem/ivakaftorjem, v primerjavi s 4,9 % pri bolnikih, ki so prejemali placebo.
The percentage of patients with hypercalciuria at the end of the 24-week extension was not statistically different between treatment groups.
Po koncu 24 tedenskega podaljška deleža bolnic s hiperkalciurijo v obeh skupinah nista bila statistično različna.
The percentage of patients with one or greater than one episodes of clinically-suspected and treated rejections during the 360-day study was 13.8% for the Envarsus group(N=268) and 15.6% for the Prograf group (N=275).
Odstotek bolnikov z eno ali več kot eno epizodo s kliničnim sumom na zavrnitev in zdravljenjem zavrnitve v 360-dnevni študiji je bila 13,8 % za skupino z zdravilom Envarsus (N = 268) in 15,6 % za skupino z zdravilom Prograf (N = 275).
The percentage of patients with vitamin D insufficiency (serum 25-hydroxyvitamin D < 37.5 nmol/l [< 15 ng/ml]) was significantly reduced by 62.5 % with ADROVANCE (70 mg/2,800 IU) vs. alendronate-only (12 % vs.
Delež bolnic s pomanjkanjem vitamina D (serumski 25-hidroksivitamin D < 37,5 nmol/l [< 15 ng/ml]) je bil v skupini, ki je prejemala zdravilo ADROVANCE (70 mg/2.800 i.e.), v 15. tednu pomembno nižji (za 62,5 %) kot v skupini, ki je prejemala le alendronat (12 % oz.
The percentage of patients with vitamin D insufficiency (serum 25-hydroxyvitamin D < 37.5 nmol/l [< 15 ng/ml]) was significantly reduced by 62.5 % with VANTAVO (70 mg/2800 IU) vs. alendronate-only (12 % vs.
Delež bolnic s pomanjkanjem vitamina D (serumski 25-hidroksivitamin D < 37,5 nmol/l [< 15 ng/ml]) je bil v skupini, ki je prejemala zdravilo VANTAVO (70 mg/2.800 i.e.), v 15. tednu pomembno nižji (za 62,5 %) kot v skupini, ki je prejemala le alendronat (12 % oz.
The percentage of some adverse reactions was higher in the 40 patients in whom the dose was increased to 800 mg daily compared to the population of patients before dose increase (n=551).
Odstotni delež nekaterih neželenih reakcij je bil večji pri tistih 40 bolnikih, pri katerih je bil odmerek zvečan na 800 mg na dan, kot pri populaciji bolnikov pred zvečanjem odmerka (n = 551).
The percentage of subjects with OPA titres  8 and GMTs observed post-primary and post-booster were lower in the 2 dose schedule than that in the 3 dose schedule.
Odstotek preiskovancev s titri OPA  8 in geometrijsko sredino titrov opaženo po primarnem cepljenju in po obnovitvenem odmerku je bil ob shemi z 2 odmerkoma nižji kot ob shemi s 3 odmerki.
The percentage of subjects with OPA titres  8 in 2-dose primed subjects compared to 3-dose primed subjects were lower for serotypes 6B, 18C and 23F (74.4%, 82.8%, 86.3% respectively for the 2-dose schedule and 88.9%, 96.2%, 97.7% respectively for the 3-dose schedule).
Za serotipe 6B, 18C in 23F je bil med preiskovanci, ki so primarno dobili 2 odmerka, manjši odstotek takšnih s titri OPA  8 (74,4 %, 82,8 %, 86,3 % po serotipih), kot med preiskovanci, ki so primarno dobili 3 odmerke (88,9 %, 96,2 %, 97,7 % po serotipih).
The percentage of subjects with rSBA titres (measured at GSK’s laboratories) ≥ 128 before vaccination ranged from 45% (group C) to 62% (group Y).
Delež oseb s titrom rSBA (izmerjenim v laboratorijih družbe GSK) ≥ 128 pred cepljenjem je znašal od 45 % (proti skupini C) do 62 % (proti skupini Y).
The percentage of subjects with suicidal ideation and/or behaviour based on the Columbia-Suicide Severity Rating Scale (C-SSRS) was similar between the varenicline and placebo groups during treatment and in the non- treatment follow-up, as shown in the following table:
Odstotek preskušancev s samomorilnimi mislimi in/ali vedenjem glede na lestvico C-SSRS (C- SSRS  Columbia Suicide Severity Rating Scale) v skupinah, ki sta prejemali vareniklin in placebo, je bil v času zdravljenja in spremljanja brez zdravljenja podoben, kot prikazuje spodnja preglednica:
The percentage of subjects with suicide-related events in the active treatment phase compared to post-treatment phase was unchanged in the varenicline group; in the placebo group, this percentage was lower in the post-treatment phase.
Delež preiskovancev s samomorom povezanimi dogodki v obdobju prejemanja zdravila v primerjavi z obdobjem po končanem prejemanju zdravila je bil nespremenjen v skupini, ki je prejemala vareniklin; v skupini, ki je prejemala placebo, je bil ta delež v obdobju po končanem prejemanju zdravila manjši.
The percentage of subjects with ≥50% reduction (1581 analyzed) in seizure frequency in the phase III studies was 19.3% for placebo, 20.8% for eslicarbazepine acetate 400 mg, 30.5% for eslicarbazepine acetate 800 mg and 35.3% for eslicarbazepine acetate 1,200 mg daily.
Odstotek bolnikov, pri katerih je prišlo do ≥ 50-odstotnega zmanjšanja (1.581 analiziranih) pogostnosti epileptičnih napadov v študijah III. faze, je 19,3 % za placebo, 20,8 % za eslikarbazepinacetat 400 mg, 30,5 % za eslikarbazepinacetat 800 mg in 35,3 % za eslikarbazepinacetat 1200 mg na dan.
The percentage of subjects with ≥50% reduction (1581 analyzed) in seizure frequency in the phase III studies was 19.3% for placebo, 20.8% for eslicarbazepine acetate 400 mg, 30.5% for eslicarbazepine acetate 800 mg and 35.3% for eslicarbazepine acetate 1,200 mg daily.
Odstotek bolnikov, pri katerih je prišlo do ≥50-odstotnega zmanjšanja (1.581 analiziranih) pogostnosti epileptičnih napadov v študijah III. faze, je 19,3 % za placebo, 20,8 % za eslikarbazepinacetat 400 mg, 30,5 % za eslikarbazepinacetat 800 mg in 35,3 % za eslikarbazepinacetat 1200 mg na dan.
The percentage of the dose of lenvatinib excreted in urine was low in all cohorts (<2.16% across treatment cohorts).
Odstotni delež v urinu izločenega odmerka lenvatiniba je bil v vseh kohortah majhen (<2,16 % v zdravljenih kohortah).
The percentages of healthy subjects with hSBA ≥1:5 were 98% for antigen fHbp, 99% for antigen NadA, 83% for antigen PorA P1.4, and 99% for antigen NHBA.
Odstotek zdravih oseb z rezultatom hSBA ≥ 1:5 je bil 98 % za antigen fHbp, 99 % za antigen NadA, 83 % za antigen PorA P1.4 in 99 % za antigena NHBA.
The percentages of patients anaemic at baseline were 46% and 35% respectively.
Odstotek slabokrvnih bolnikov ob izhodišču je bil 46 % oziroma 36 %.
The percentages of subjects with hSBA ≥ 1:8 remained constant against serogroups C, W135, and Y from 21 months to 5 years postvaccination in the Menveo group and decreased slightly over time against serogroup A (Table 6).
Odstotek oseb s hSBA ≥ 1 : 8 je ostajal stalen pri odzivu na seroskupine C, W135 in Y od 21 mesecev do 5 let po cepljenju v skupini, ki je prejela cepivo Menveo, in se je sčasoma nekoliko nižal pri odzivu na seroskupino A (tabela 6).
The percentages of subjects with ≥5% or ≥10% body weight loss from baseline were greater with naltrexone / bupropion compared to placebo in all four Phase 3 obesity trials (Table 3).
Odstotek preiskovancev, ki so zmanjšali telesno maso za ≥5 % ali ≥10 % glede na izhodiščno vrednost, je bil pri uporabi naltreksona/bupropiona večji kot pri uporabi placeba v vseh štirih preskušanjih 3. faze glede debelosti (Preglednica 3).
The percentages of successful injections for the two groups were around 30% and 9%, respectively.
Delež uspešnih injekcij za obe skupini je znašal okoli 30 % oziroma 9 %.
The percentages with anti-HBs antibody ≥10 mIU/ml at this time point for subjects vaccinated at the 0, 6 and 0, 12 month schedules were 84.8% and 92.9%, respectively.
Delež protiteles anti-HBs ≥10 mi.e./ml je bil pri osebah, cepljenih po shemi 0., 6. mesec ali 0., 12. mesec, ob tem času 84,8 % pri prvih in 92,9 % pri drugih.
The performance status scale, for head and neck (PSS-HN) subscales designed to measure understandability of speech, ability to eat in public, and normalcy of diet, was significantly in favor of TPF as compared to PF.
Lestvica stanja zmogljivosti s podlestvicama za glavo in vrat (PSS-HN), namenjenima merjenju razumljivosti govora, sposobnosti uživanja hrane na javnem mestu in normalnosti hrane , je signifikantno govorila v korist TPF v primerjavi s PF.
The perfusion tubing is connected to the Y-connection.
Povežite perfuzijsko cevko s spojem Y.
The perfusor syringe must be changed at least every 12 hours after the start of the infusion.
Brizgo perfuzorja je treba zamenjati najmanj vsakih 12 ur po nastavitvi infuzije.
The perfusor syringe must be changed at least every 12 hours after the start of the infusion.
Brizgo perfuzorja je treba zamenjati vsaj vsakih 12 ur po začetku infuzije.
The period during which the disease did not get worse in this group of patients was also higher with Keytruda: around 5 months versus 4 months with docetaxel.
Tudi obdobje, v katerem se bolezen ni poslabšala, je bilo v tej skupini bolnikov daljše kot pri zdravilu Keytruda: približno 5 mesecev v primerjavi s 4 meseci z docetakselom.
The period of enrolment to the study (December 2003 – December 2006) preceded the adoption of trastuzumab in combination with an aromatase inhibitor.
Obdobje vključevanja v študijo (od decembra 2003 do decembra 2006) je bilo še pred sprejetjem trastuzumaba v kombinaciji z zaviralcem aromataze.
The period of onset of hepatocellular injury (by ALT elevations >3xULN) was within 3 to 14 months after initiating treatment and these increases were reversible, with ALT returning to <3xULN within 1 to 4 months.
Obdobje nastopa poškodovanja jetrnih celic (zvišanje ALT > 3 x ULN) je bilo v 3 do 14 mesecih po uvedbi zdravljenja, pri čemer so bila ta zvišanja reverzibila, vrednosti ALT pa so se na < 3 x ULN vrnile v 1 do 4 mesecih.
The periodic safety update report (PSUR) cycle should be restarted for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals, unless otherwise required.
Cikel rednih posodobljenih poročil o varnosti zdravila (PSUR) se ponovno začne z oddajo šestmesečnih poročil (vključene so vse odobrene oblike zdravila) v obdobju naslednjih dveh let, ki mu sledi oddaja dveh letnih poročil za naslednji dve leti, po tem obdobju pa se poročila oddajajo v triletnih obdobjih , razen če je zahtevano drugače.
The periodic safety update report (PSUR) cycle should be restarted for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals, unless otherwise required.
Cikel rednih posodobljenih poročil o varnosti zdravila (PSUR) se ponovno začne z oddajo šestmesečnih poročil (vključene so vse odobrene oblike zdravila) v obdobju naslednjih dveh let, ki mu sledi oddaja dveh letnih poročil za naslednji dve leti, po tem obdobju pa se poročila oddajajo v triletnih obdobjih, razen če je zahtevano drugače.
The periodic safety update report (PSUR) cycle should be restarted for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals.
Cikel rednih posodobljenih poročil o varnosti zdravila (PSUR) se ponovno začne z oddajo šest mesečnih poročil (vključene so vse odobrene oblike zdravila) v obdobju naslednjih dveh let, ki mu sledi oddaja dveh letnih poročil za naslednji dve leti, po tem obdobju pa se poročila oddajajo v triletnih obdobjih.
The periodic safety update report (PSUR) cycle should be restarted for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals. .
Cikel oddaje poročil o varnosti zdravila (PSUR) se ponovno začne z oddajo 6-mesečnih poročil (za vsa odobrena pakiranja cepiva) v naslednjih 2 letih, čemur sledi oddaja letnih poročil v 2 letih kasneje, nato pa v 3-letnih intervalih.
The persistence of antibody response following a complete schedule of vaccination with Gardasil 9 is being studied in a subset of individuals who will be followed up for at least 10 years after vaccination for safety, immunogenicity and effectiveness.
Trajanje odziva protiteles po dokončanem cepljenju z vsemi odmerki cepiva Gardasil 9 proučujejo v podskupini oseb, ki jih bodo vsaj 10 let po cepljenju spremljali glede varnosti, imunogenosti in učinkovitosti.
The persistence of JEV neutralizing antibodies after primary immunisation and safety and immunogenicity of an IXIARO booster dose 12 months after primary immunization were evaluated in a randomized, controlled, open-label clinical trial conducted in the Philippines, where JEV is endemic (300 children, mean age 5.3 years, range 1.2 - 17.3 years).
Vztrajnost nevtralizirajočih protiteles proti virusu japonskega encefalitisa po primarni imunizaciji ter varnost in imunogenost obnovitvenega odmerka zdravila IXIARO 12 mesecev po primarni imunizaciji so bile ocenjene v randomizirani, nadzorovani, odprti klinični raziskavi na Filipinih, kjer je virus japonskega encefalitisa endemičen (300 otrok, povprečna starost 5,3 leta, razpon 1,2–17,3 leta).
The persistence of the immune response elicited by Nimenrix was evaluated up to 60 months after vaccination in subjects aged 12 months to 55 years.
Trajanje imunskega odziva na cepivo Nimenrix so do 60 mesecev po cepljenju ocenili pri preskušancih, starih od 12 mesecev do 55 let.
The person administering Panacur AquaSol should avoid contact with his/her skin, eye and moist body surfaces (mucous membranes) as the medicine may cause reactions, including skin irritation.
Oseba, ki daje zdravilo Panacur AquaSol, naj se izogiba stiku s kožo, očmi in vlažnimi telesnimi površinami (sluznico), saj lahko zdravilo povzroči reakcije, vključno z draženjem kože.
The person administering Procox should avoid contact with their skin or eyes.
Oseba, ki daje zdravilo Procox se mora izogibati stiku zdravila s kožo ali očmi.
The person administering Semintra should avoid getting it in their eyes.
Oseba, ki daje zdravilo Semintra, mora paziti, da to ne pride v oči.
The person who gives the vaccine should be careful to avoid accidental self injection.
Oseba, ki daje cepivo, mora paziti, da si zdravila po nesreči ne samo- injicira.
The person who injects the vaccine should be careful to avoid accidental self injection.
Oseba, ki daje cepivo, mora paziti, da si zdravila po nesreči ne samo- injicira.
The PET results were compared with the maximal neuritic plaque density measured on sections of frontal, temporal or parietal cortex at the patient’s autopsy within 24 months of PET scan.
Rezultate PET-preiskave so primerjali z maksimalno gostoto nevritičnih leh, izmerjeno na delih frontalne, temporalne ali parietalne skorje med obdukcijo bolnika v 24 mesecih po PET-preiskavi.